PERSONAL INFORMATION Ronald van Schaik · M(1), van den Broek MPH(4)(5), de Bruin-Weller MS(1). Thiopurine metabolite levels in patients with atopic dermatitis and/or chronic hand/foot

Curriculum vitae

PERSONAL INFORMATION Ronald van Schaik

WORK EXPERIENCE

1987–1992 PhD studentUtrecht University (Netherlands)

Setting up molecular biology at Dept. Biochemistry; characterization and cloning of phospholipase A2

1992–1996 Post-DocAcademic Hospital Rotterdam (Netherlands)

Setting up molecular biology laboratory at the Dept Endocrinology and performing molecular biology research in oncology (germ cell tumors, prostate-, breast- and ovarian cancer


Development of molecular biological screening for colon cancer


Setting up molecular biology laboratory at the Dept Clinical Chemistry; performing molecular biology research in pharmacogenetics

2003–2013 European Specialist Laboratory MedicineErasmus MC (Netherlands)

Responsible for clinical chemistry testing on Pharmacogenetics, Cardiac Markers, Prostate Cancer, Kidney Stones and Point-of-Care Testing; Pharmacogenetic Research and Prostate Cancer Research

2013–Present Full Professor PharmacogeneticsErasmus MC (Netherlands)

Responsible for clinical chemistry testing on Pharmacogenetics, Cardiac Markers, Prostate Cancer; Pharmacogenetic Research and Prostate Cancer Research

October 2015–Present Deputy Head Dept. Clinical ChemistryErasmus MC (Netherlands)

EDUCATION AND TRAINING

1981–1987 (Bio)ChemistryUtrecht University (Netherlands)

1988–1989 Molecular BiologyCold Spring Harbor Laboratories, NY (United States)

Molecular Biology

2008–2008 NIHESErasmus MC (Netherlands)

Statistics

26/12/18 © European Union, 2002-2018 | http://europass.cedefop.europa.eu Page 1 / 20

Curriculum vitae Ronald van Schaik

1993–1993 Summerschool Endocrinology & ImmunologyErasmus MC (Netherlands)

Endocrinology & Immunology

2003–2003 Clinical Pharmacology Curriculum Review CourseASCPT (Netherlands)

Clinical Pharmacology

2010–2010 Leadership ProgramErasmus MC (Netherlands)

Management

ADDITIONAL INFORMATION

Expertise Pharmacogenetics

Publications 2017

1. Zhu L(1), Brüggemann RJ(2), Uy J(3), Colbers A(2), Hruska MW(1), Chung E(4), Sims K(1), Vakkalagadda B(4), Xu X(5), van Schaik RH(6), Burger DM(2), Bertz RJ(4). CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects. J Clin Pharmacol. 2017 Feb;57(2):235-246.

2. Danesi R(1), Del Re M(1), Ciccolini J(2), Schellens JHM(3), Schwab M(4), van Schaik RHN(5), van Kuilenburg ABP(6). Prevention of fluoropyrimidine toxicity: do we still have to try our patient`s luck? Ann Oncol. 2017 Jan 1;28(1):183.

3. Del Re M(1), Biasco E(2), Crucitta S(3), Derosa L(2), Rofi E(3), Orlandini C(2), Miccoli M(4), Galli L(2), Falcone A(2), Jenster GW(5), van Schaik RH(6), Danesi R(3). The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol. 2017 Apr;71(4):680-687.

4. Baggen VJ(1), van den Bosch AE(1), Eindhoven JA(1), Schut AW(1), Cuypers JA(1), Witsenburg M(1), de Waart M(1), van Schaik RH(1), Zijlstra F(1), Boersma E(1), Roos-Hesselink JW(2). Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide, Troponin-T, and Growth-DifferentiationFactor 15 in Adult Congenital Heart Disease. Circulation. 2017 Jan 17;135(3):264-279.

5. Andreu F(1)(2), Colom H(2), Elens L(3)(4), van Gelder T(5)(6)(4), van Schaik RHN(6)(4), Hesselink DA(5)(4), Bestard O(1), Torras J(1), Cruzado JM(1), Grinyó JM(1), Lloberas N(7). A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. Clin Pharmacokinet. 2017 Aug;56(8):963-975.

6. Fragoulakis V(1)(2), Mitropoulou C(3)(4), Katelidou D(5), van Schaik RH(3), Maniadakis N(2), Patrinos GP(1). Performance Ratio Based Resource Allocation Decision-Making in Genomic Medicine. OMICS. 2017 Feb;21(2):67-73.

7. Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Ba?ak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Káda?i ?, Ku?inskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Serti? J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP. Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications forClinical Pharmacogenomics. PLoS One. 2017 Feb 16;12(2):e0172595.

8. Lammers LA(1), Achterbergh R(2), van Schaik RH(3), Romijn JA(2), Mathôt RA(4). Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach. Clin Pharmacokinet. 2017 Feb 22.

9. Woillard JB(1), Mourad M(2), Neely M(3), Capron A(4), van Schaik RH(5), van Gelder T(6)(7), Lloberas N(8), Hesselink DA(7), Marquet P(1), Haufroid V(4)(9), Elens L(9)(10). Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior



to Kidney Transplantation. Front Pharmacol. 2017 Jun 8;8:358.

10. Matic M(1), van den Bosch GE, de Wildt SN, Tibboel D, van Schaik RHN. Reply. Pain. 2017 Aug;158(8):1623.

11. Andrews LM(1), Hesselink DA(2), van Gelder T(3)(2), Koch BCP(3), Cornelissen EAM(4), Brüggemann RJM(5), van Schaik RHN(6), de Wildt SN(7), Cransberg K(8), de Winter BCM(3). A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. Clin Pharmacokinet. 2017 Jul 5.

12. Matic M(1)(2), de Wildt SN(2)(3), Tibboel D(2), van Schaik RHN(4). Analgesia and Opioids: A Pharmacogenetics Shortlist for Implementation in Clinical Practice. Clin Chem. 2017 Jul;63(7):1204-1213.

13. Lloberas N(1), Elens L, Llaudó I, Padullés A, van Gelder T, Hesselink DA, Colom H, Andreu F, Torras J, Bestard O, Cruzado JM, Gil-Vernet S, van Schaik R, Grinyó JM. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. Pharmacogenet Genomics. 2017 Jul 12.

14. Matic M(1)(2), Jongen JL(3), Elens L(4)(5), de Wildt SN(2)(6), Tibboel D(2), Sillevis Smitt PA(3), van Schaik RH(1). Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement. Pharmacogenomics. 2017 Jul 26.

15. Stathopoulou MG(1), Xie T(1), Ruggiero D(1), Chatelin J(1), Rancier M(1), Weryha G(1), Kurth MJ(1), Aldasoro Arguinano AA(1), Gorenjak V(1), Petrelis AM(1), Dagher G(1), Dedoussis G(1), Deloukas P(1), Lamont J(1), Marc J(1), Simmaco M(1), Schaik RHNV(1), Innocenti F(1), Merlin JL(1), Schneider J(1), Alizadeh BZ(1), Ciullo M(1), Seshadri S(1), Visvikis-Siest S(1); VEGF Consortium. A transnational collaborative network dedicated to the study and applications of the vascular endothelial growth factor-A in medical practice: the VEGF Consortium. Clin Chem Lab Med. 2017 Oct 31. pii: /j/cclm.ahead-of-print/cclm-2017-0838/cclm-2017-0838.xml.

16. Garritsen FM(1), van der Schaft J(1), Bruijnzeel-Koomen CAF(1), van Schaik RH(2)(3), de Graaf M(1), van den Broek MPH(4)(5), de Bruin-Weller MS(1). Thiopurine metabolite levels in patients with atopic dermatitis and/or chronic hand/foot eczema treated with azathioprine. J Dermatolog Treat. 2017Sep 26:1-8.

17. Del Re M(1), Biasco E(2), Crucitta S(3), Derosa L(2), Rofi E(3), Orlandini C(2), Miccoli M(4), Galli L(2), Falcone A(2), Jenster GW(5), van Schaik RH(6), Danesi R(3). Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol. 2017 Aug 8. pii: S0302-2838(17)30663-2.

18. Del Re M(1), Bordi P(2), Petrini I(3), Rofi E(1), Mazzoni F(4), Belluomini L(5), Vasile E(3), RestanteG(1), Di Costanzo F(4), Falcone A(3), Frassoldati A(5), van Schaik RHN(6), Steendam CMJ(7), Chella A(8), Tiseo M(2), Morganti R(9), Danesi R(1). Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment. Oncotarget. 2017 Sep 15;8(49):86056-86065.

19. Andrews LM(1), de Winter BC(1), Tang JT(2), Shuker N(1), Bouamar R(1), van Schaik RH(3), Koch BC(1), van Gelder T, Hesselink DA(4). Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose. Transplant Direct.2017 Jan 19;3(2):e129.

20. Ekhart C(1), Matic M(2), Kant A(1), van Puijenbroek E(1)(3), Schaik RV(2). CYP450 genotype andaggressive behavior on selective serotonin reuptake inhibitors. Pharmacogenomics. 2017 May;18(7):613-620.

21. Fattah S(1), Shinde AB(2), Matic M(3)(4), Baes M(2), van Schaik RHN(3), Allegaert K(4)(5), Parmentier C(6), Richert L(6)(7), Augustijns P(1), Annaert P(8). Inter-Subject Variability in OCT1 Activity in 27 Batches of Cryopreserved Human Hepatocytes and Association with OCT1 mRNA Expression and Genotype. Pharm Res. 2017 Jun;34(6):1309-1319.

2016

1. Crona DJ(1), Ramirez J(2), Qiao W(3), de Graan AJ(4), Ratain MJ(2), van Schaik RH(5), Mathijssen RH(4), Rosner GL(6), Innocenti F(1,)(2,)(7). Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. 2016 Feb;16(1):54-9.doi: 10.1038/tpj.2015.23. Epub 2015 Apr 14.

2. van der Schaft J(1), van Schaik RH(2), van Zuilen AD(3), Hijnen DJ(4), Berg MT(5), van den Broek MP(6), Bruijnzeel-Koomen CA(4), de Bruin-Weller MS(4). First experience with extended release tacrolimus in the treatment of adult patients with severe, difficult to treat atopic dermatitis: Clinical efficacy, safety and dose finding. J Dermatol Sci. 2016 Jan;81(1):66-8. doi: 10.1016/j.jdermsci.2015.10.013. Epub 2015 Oct 28.



3. Kalman LV(1), AgÃºndez J(2), Appell ML(3), Black JL(4), Bell GC(5), Boukouvala S(6), Bruckner C(7), Bruford E(8), Caudle K(9), Coulthard SA(10), Daly AK(10), Tredici AD(11), den Dunnen JT(12), Drozda K(13), Everts RE(14), Flockhart D(15), Freimuth RR(4), Gaedigk A(16), Hachad H(17), Hartshorne T(18), Ingelman-Sundberg M(19), Klein TE(20), Lauschke VM(19), Maglott DR(21), McLeod HL(5), McMillin GA(22), Meyer UA(23), MÃ¼ller DJ(24), Nickerson DA(25), Oetting WS(26), Pacanowski M(13), Pratt VM(15), Relling MV(9), Roberts A(27), Rubinstein WS(21), Sangkuhl K(20), Schwab M(28), Scott SA(29), Sim SC(19), Thirumaran RK(30), Toji LH(31), Tyndale RF(32), van Schaik R(33), Whirl-Carrillo M(20), Yeo K(34), Zanger UM(28). Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clin Pharmacol Ther. 2016 Feb;99(2):172-85. doi: 10.1002/cpt.280. Epub 2015 Nov 20.

4. Eindhoven JA(1), van den Bosch AE(1), Oemrawsingh RM(1), Baggen VJ(1), Kardys I(1), Cuypers JA(1), Witsenburg M(1), van Schaik RH(2), Roos-Hesselink JW(3), Boersma E(1). Release of growth-differentiation factor 15 and associations with cardiac function in adult patients with congenital heart disease. Int J Cardiol. 2016 Jan 1;202:246-51. doi: 10.1016/j.ijcard.2015.09.010. Epub 2015 Sep 14.

5. Blonk MI(1), Langemeijer CC, Colbers AP, Hoogtanders KE, van Schaik RH, Schouwenberg BJ, Burger DM. Pharmacokinetic drug-drug interaction study between raltegravir and citalopram. Antivir Ther. 2016;21(2):143-52. doi: 10.3851/IMP2993. Epub 2015 Sep 16.

6. Oemrawsingh RM(1), Cheng JM(2), GarcÃ¬a-GarcÃ¬a HM(3), Kardys I(2), van Schaik RH(4), Regar E(2), van Geuns RJ(2), Serruys PW(2), Boersma E(5), Akkerhuis KM(2). High-sensitivity Troponin T in relation to coronary plaque characteristics in patients with stable coronary artery disease; results of the ATHEROREMO-IVUS study. Atherosclerosis. 2016 Feb 15;247:135-141. doi: 10.1016/j.atherosclerosis.2016.02.012. [Epub ahead of print]

7. Mitrov-Winkelmolen L(1), van Buul-Gast MW(2), Swank DJ(3), Overdiek HW(4), van Schaik RH(5), Touw DJ(6). The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study. Obes Surg. 2016 Jan 21. [Epub ahead of print]

8. Vet NJ(1), Brussee JM(2), de Hoog M(3), Mooij MG(4), Verlaat CW(5), Jerchel IS(6), van Schaik RH(7), Koch BC(8), Tibboel D(9), Knibbe CA(10,)(11), de Wildt SN(12); SKIC (Dutch collaborative PICU research network). Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children. Am J Respir Crit Care Med. 2016 Jan 21. [Epub ahead of print]

9. Shuker N(1,)(2), Bouamar R(2), van Schaik RH(3), Clahsen-van Groningen MC(4), Damman J(5), Baan CC(1), van de Wetering J(1), Rowshani AT(1), Weimar W(1), van Gelder T(1,)(2), Hesselink DA(1). A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation. Am J Transplant. 2016 Jul;16(7):2085-96. doi: 10.1111/ajt.13691. Epub 2016 Feb 26.

10. Tang JT(1,)(2), Andrews LM(2), van Gelder T(2,)(3), Shi YY(4), van Schaik RH(5), Wang LL(1), Hesselink DA(3). Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin Drug Metab Toxicol. 2016 Apr 7:1-11. [Epub ahead of print]

11. Elens L(1), Elisabeth N, Maja M, Rane A, Fellman V, van Schaik RH. Genetic predisposition to poor opioid response in preterm infants: Impact of KCNJ6 and COMT polymorphisms on pain relief after endotracheal intubation. Ther Drug Monit. 2016 Mar 17. [Epub ahead of print]

12. Del Re M(1), Citi V(2), Crucitta S(2), Rofi E(2), Belcari F(2), van Schaik RH(3), Danesi R(2). Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? Pharmacol Res.2016 Apr 8;107:398-406. doi: 10.1016/j.phrs.2016.03.025. [Epub ahead of print]

13. Matic M(1), de Wildt SN, Elens L, de Hoon JN, Annaert P, Tibboel D, van Schaik RH, Allegaert K. SLC22A1 /OCT1 genotype affects O-desmethyltramadol exposure in new-born infants. Ther Drug Monit. 2016 Apr 14. [Epub ahead of print]

14. Fragoulakis V(1,)(2), Mitropoulou C(3), van Schaik RH(3), Maniadakis N(2), Patrinos GP(1). An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic Medicine. OMICS. 2016 Apr 20. [Epub ahead of print]

15. Teeninga N(1), Guan Z, Stevens J, Kist-van Holthe JE, Ackermans MT, van der Heijden AJ, van Schaik RH, van Gelder T, Nauta J. Population Pharmacokinetics of Prednisolone in Relation to Clinical Outcome in Children With Nephrotic Syndrome. Ther Drug Monit. 2016 Aug;38(4):534-45. doi:10.1097/FTD.0000000000000308.

16. Prytula AA(1,)(2), Cransberg K(3), Bouts AH(4), van Schaik RH(5), de Jong H(3), de Wildt SN(6), MathÃ´t RA(7). The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. Clin Pharmacokinet. 2016 Apr 30. [Epub ahead of print]

17. Payne DA(1), Baluchova K(2), Peoc`h KH(3), van Schaik RH(4), Chan KC(5), Maekawa M(6),



Mamotte C(7), Russomando G(8), Rousseau F(9), Ahmad-Nejad P(10); IFCC Committee for Molecular Diagnostics (C-MD). Pre-examination factors affecting molecular diagnostic test results and interpretation: A case-based approach. Clin Chim Acta. 2016 Jun 16. pii: S0009-8981(16)30263-7. doi: 10.1016/j.cca.2016.06.018. [Epub ahead of print]

18. Oosten AW(1), Matic M(2,)(3), van Schaik RH(2), Look MP(1), Jongen JL(4), Mathijssen RH(1), van der Rijt CC(1,)(5). Opioid treatment failure in cancer patients: the role of clinical and genetic factors. Pharmacogenomics. 2016 Jul 29. [Epub ahead of print]

19. Thijs JL(1), Van Der Geest BA(1), Van Der Schaft J(1), Van Den Broek MP(2), Van Seggelen WO(1), Bruijnzeel-Koomen CA(1), Hijnen DJ(1), Van Schaik RH(3,)(4), De Bruin-Weller MS(1). Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis. J Dermatolog Treat. 2016 Sep 13:1-4. [Epub ahead of print]

20. Kumuthini J(1), Mbiyavanga M(1), Chimusa ER(1,)(2), Pathak J(3), Somervuo P(4), Van Schaik RH(5), Dolzan V(6), Mizzi C(7,)(8), Kalideen K(9), Ramesar RS(9), Macek M(10), Patrinos GP(7,)(11),Squassina A(12). Minimum information required for a DMET experiment reporting. Pharmacogenomics. 2016 Sep;17(14):1533-45. doi: 10.2217/pgs-2016-0015. Epub 2016 Aug 22.

21. Matic M(1), van den Bosch GE, de Wildt SN, Tibboel D, van Schaik RH. Genetic variants associated with thermal pain sensitivity in a paediatric population. Pain. 2016 Jul 14. [Epub ahead of print]

22. Bins S(1), Lenting A(1), El Bouazzaoui S(2), van Doorn L(1), Oomen-de Hoop E(1), Eskens FA(1),van Schaik RH(2), Mathijssen RH(1). Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity. Pharmacogenomics. 2016 Sep;17(14):1483-90. doi: 10.2217/pgs-2016-0063. Epub 2016 Aug 17.

23. Zhou K(1), Yee SW(2), Seiser EL(3), van Leeuwen N(4), Tavendale R(1), Bennett AJ(5), Groves CJ(5), Coleman RL(6), van der Heijden AA(7), Beulens JW(8,)(9), de Keyser CE(10), Zaharenko L(11,)(12), Rotroff DM(13,)(14), Out M(15,)(16), Jablonski KA(17), Chen L(18), JavorskÃ½ M(19), ?idzik J(19), Levin AM(20), Williams LK(21,)(22), Dujic T(1,)(23), Semiz S(23,)(24), Kubo M(25), Chien HC(2), Maeda S(26,)(27), Witte JS(28,)(29,)(30,)(31), Wu L(28), TkÃ¡? I(19), Kooy A(15,)(16), van Schaik RH(32), Stehouwer CD(33), Logie L(1); MetGen Investigators; DPP Investigators; ACCORD Investigators, Sutherland C(1), Klovins J(11,)(12), Pirags V(12,)(34,)(35), Hofman A(10), Stricker BH(10,)(36), Motsinger-Reif AA(13), Wagner MJ(37), Innocenti F(3), Hart LM(4,)(8,)(38), Holman RR(6), McCarthy MI(5,)(39,)(40), Hedderson MM(41), Palmer CN(1), Florez JC(18,)(42,)(43,)(44), Giacomini KM(2,)(29), Pearson ER(1). Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet. 2016 Sep;48(9):1055-9. doi: 10.1038/ng.3632. Epub 2016 Aug 8.

24. Mijderwijk H(1), Klimek M, van Beek S, van Schaik RH, Duivenvoorden HJ, Stolker RJ. Implicationof UGT2B15 Genotype Polymorphism on Postoperative Anxiety Levels in Patients Receiving Lorazepam Premedication. Anesth Analg. 2016 Sep 12. [Epub ahead of print]

25. Mizzi C(1,)(2), Dalabira E(3), Kumuthini J(4), Dzimiri N(5), Balogh I(6), Ba?ak N(7), BÃ¶hm R(8), Borg J(9), Borgiani P(10), Bozina N(11), Bruckmueller H(8), Burzynska B(12), Carracedo A(13), Cascorbi I(8), Deltas C(14), Dolzan V(15), Fenech A(16), Grech G(16), Kasiulevicius V(17), KÃ¡da?i ?(18,)(19), Ku?inskas V(17), Khusnutdinova E(20,)(21), Loukas YL(22), Macek M Jr(23), Makukh H(24), Mathijssen R(25), Mitropoulos K(26), Mitropoulou C(25), Novelli G(10), Papantoni I(3), PavlovicS(27), Saglio G(28), Setric J(11,)(29), Stojiljkovic M(27), Stubbs AP(1), Squassina A(30), Torres M(13),Turnovec M(23), van Schaik RH(25), Voskarides K(14), Wakil SM(5), Werk A(8), Del Zompo M(30), Zukic B(27), Katsila T(3), Lee MT(31), Motsinger-Rief A(32), Mc Leod HL(33), van der Spek PJ(1), Patrinos GP(1,)(3). A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS One. 2016 Sep 16;11(9):e0162866. doi: 10.1371/journal.pone.0162866. eCollection 2016.

26. Vozikis A(1), Cooper DN, Mitropoulou C, Kambouris ME, Brand A, Dolzan V, Fortina P, Innocenti F, Lee MT, Leyens L, Macek M Jr, Al-Mulla F, Prainsack B, Squassina A, Taruscio D, van Schaik RH, Vayena E, Williams MS, Patrinos GP. Test Pricing and Reimbursement in Genomic Medicine: Towardsa General Strategy. Public Health Genomics. 2016 Sep 28. [Epub ahead of print]

27. Danesi R(1), Del Re M(2), Ciccolini J(3), Schellens JH(4), Schwab M(5), van Schaik RH(6), van Kuilenburg AB(7). Prevention of fluoropyrimidine toxicity: do we still have to try our patient`s luck? Ann Oncol. 2016 Sep 29. pii: mdw448. [Epub ahead of print]

28. Del Re M(1), Biasco E(2), Crucitta S(3), Derosa L(2), Rofi E(3), Orlandini C(2), Miccoli M(4), Galli L(2), Falcone A(2), Jenster GW(5), van Schaik RH(6), Danesi R(3). The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol. 2016 Aug 26. pii: S0302-2838(16)30479-1. doi: 10.1016/j.eururo.2016.08.012. [Epub ahead of print]

29. Loeb S(1), Shin SS(2), Broyles DL(2), Wei JT(3), Sanda M(4), Klee G(5), Partin AW(6), Sokoll



L(7), Chan DW(7), Bangma CH(8), van Schaik RH(9), Slawin KM(10), Marks LS(11), Catalona WJ(12). Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int. 2016 Oct 15. doi: 10.1111/bju.13676. [Epub ahead of print]

30. Mitropoulou C(1), Fragoulakis V(2,)(3), Rakicevic LB(4), Novkovic MM(4), Vozikis A(5), Matic DM(6), Antonijevic NM(7,)(8), Radojkovic DP(4), van Schaik RH(1), Patrinos GP(2). Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. Pharmacogenomics. 2016 Oct 21. [Epub ahead of print]

31. Oosten AW(1), Abrantes JA(2), JÃ¶nsson S(2), Matic M(3,)(4), van Schaik RH(3), de Bruijn P(5), van der Rijt CC(5,)(6), Mathijssen RH(5). A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. Clin Pharmacokinet. 2016 Nov 5. [Epub ahead of print]

32. Baggen VJ(1), van den Bosch A(2), Eindhoven JA(1), Schut AR(2), Cuypers JA(2), Witsenburg M(2), de Waart M(3), van Schaik RH(3), Zijlstra F(2), Boersma E(4), Roos-Hesselink JW(5). Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide, Troponin-T, and Growth-DifferentiationFactor 15 in Adult Congenital Heart Disease. Circulation. 2016 Nov 3. pii: CIRCULATION AHA.116.023255. [Epub ahead of print]

33. Wens SC(1), Schaaf GJ(1), Michels M(1), Kruijshaar ME(1), van Gestel TJ(1), In `t Groen S(1), Pijnenburg J(1), Dekkers DH(1), Demmers JA(1), Verdijk LB(1), Brusse E(1), van Schaik RH(1), van der Ploeg AT(1), van Doorn PA(2), Pijnappel WW(2). Elevated Plasma Cardiac Troponin T Levels Caused by Skeletal Muscle Damage in Pompe Disease. Circ Cardiovasc Genet. 2016 Feb;9(1):6-13. doi: 10.1161/CIRCGENETICS.115.001322. Epub 2016 Jan 19.

34. Zhu L(1), BrÃ¼ggemann RJ(2), Uy J(3), Colbers A(2), Hruska MW(1), Chung E(4), Sims K(1), Vakkalagadda B(4), Xu X(5), van Schaik RH(6), Burger DM(2), Bertz RJ(4). CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects. J Clin Pharmacol. 2016 Jul 19. doi: 10.1002/jcph.798. [Epub ahead of print]

2015

35. Birdwell KA(1), Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, HeY, Swen JJ, Leeder JS, van Schaik RH, Thummel KE, Klein TE, Caudle KE, MacPhee IA. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015 Mar 18. doi: 10.1002/cpt.113. [Epub ahead of print]

36. de Jonge H(1), Elens L(2), de Loor H(1), van Schaik RH(3), Kuypers DR(1). The CYP3A4*22 C>Tsingle nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. Pharmacogenomics J. 2015 Apr;15(2):144-52. doi: 10.1038/tpj.2014.49. Epub 2014 Oct 7.

37. Malentacchi F, Mancini I, Brandslund I, Vermeersch P, Schwab M, Marc J, van Schaik RH, Siest G, Theodorsson E, Pazzagli M, Di Resta C; European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Ã¢â‚¬â€œ European Society of Pharmacogenomics and Personalised Therapy (ESPT) Joint Working Group on Personalized Laboratory Medicine (WG-PLM). Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe. Clin Chem Lab Med. 2015 Apr 17. pii: /j/cclm.ahead-of-print/cclm-2015-0171/cclm-2015-0171.xml. doi: 10.1515/cclm-2015-0171. [Epu

38. de Graan AM(1), Sparreboom A(1,)(2), de Bruijn P(1), de Jonge E(3), van der Holt B(4), Wiemer EA(1), Verweij J(1), Mathijssen RH(1), van Schaik RH(3). 4ÃŽÂ²-Hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. Br J Clin Pharmacol. 2015 Jun 28. doi: 10.1111/bcp.12707. [Epub ahead of print]

39. Welzen ME(1), DezentjÃƒÂ© VO, van Schaik RH, Colbers AP, Guchelaar HJ, van Erp NP, den Hartigh J, Burger DM, van Laarhoven HW. The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity. Ther Drug Monit. 2015 Aug;37(4):501-507.

40. Langman L, van Gelder T, van Schaik RHN Pharmacogenomic aspect of immunosuppressant therapy IN: Personalized Immunosuppression in Transplantation, Eds.: Oellerich, DasGupta, 2015 Elsevier; Chapter 5 (ISBN 978-0-12-800885

41. Nieuweboer AJ(1), Smid M(1), de Graan AM(1), Elbouazzaoui S(2), de Bruijn P(1), Eskens FA(1), Hamberg P(3), Martens JW(1), Sparreboom A(4), de Wit R(1), van Schaik RH(2), Mathijssen RH(1). Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics. Pharmacogenomics J. 2015 Sep 8. doi: 10.1038/tpj.2015.66. [Epub ahead of print]

42. Weigel JD(1), Hunfeld NG(2,)(3), Koch BC(3), Egal M(2), Bakker J(2), van Schaik RH(4), van Gelder T(3,)(5). Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series. Intensive Care Med. 2015 Nov;41(11):2013-4. doi: 10.1007/s00134-015-4002-z. Epub 2015 Aug 4.



43. Nieuweboer AJ(1), Smid M(1), de Graan AJ(1), Elbouazzaoui S(2), Bruijn Pd(1), Martens JW(1), Mathijssen RH(1), van Schaik RH(2). Predicting paclitaxel-induced neutropenia using the DMET platform. Pharmacogenomics. 2015 Jul;16(11):1-11. doi: 10.2217/pgs.15.68. Epub 2015 Aug 12.

44. van der Schaft J(1), van Schaik RH(2,)(3), van den Broek MP(4), Bruijnzeel-Koomen CA(1), de Bruin-Weller MS(1). Increased liver enzyme levels during azathioprine treatment; beware of concomitant use of proton pump inhibitors. Br J Dermatol. 2015 Jul 3. doi: 10.1111/bjd.14006. [Epub ahead of print]

45. Crona DJ(1), Ramirez J(2), Qiao W(3), de Graan AJ(4), Ratain MJ(2), van Schaik RH(5), Mathijssen RH(4), Rosner GL(6), Innocenti F(7). Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. 2015 Apr 14. doi: 10.1038/tpj.2015.23. [Epub ahead of print]

46. Kraff S(1), Nieuweboer AJ, Mathijssen RH, Baty F, de Graan AJ, van Schaik RH, Jaehde U, Joerger M. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicitybased on a single sample strategy. Cancer Chemother Pharmacol. 2015 May;75(5):975-83. doi: 10.1007/s00280-015-2724-9. Epub 2015 Mar 12.

47. Joerger M(1), van Schaik RH(2), Becker ML(3), Hayoz S(4), Pollak M(5), Cathomas R(6), Winterhalder R(7), Gillessen S(1), Rothermundt C(1). Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer Prostatic Dis. 2015 Jun;18(2):167-72. doi: 10.1038/pcan.2015.8. Epub 2015 Mar 10.

48. Traynor C(1), Conlon P Jr, Phelan PJ, O`Kelly P, Elens L, McCormack M, Cavalleri G, Comber H, van Schaik RH, Conlon PJ. Association of CYP3A variants with kidney transplant outcomes. Ren Fail.2015 May;37(4):562-6. doi: 10.3109/0886022X.2015.1007013. Epub 2015 Feb 3.

49. van der Schaft J(1), van Schaik RH(2), van Zuilen AD(3), Hijnen DJ(4), Berg MT(5), van den Broek MP(6), Bruijnzeel-Koomen CA(4), de Bruin-Weller MS(4). First experience with extended release tacrolimus in the treatment of adult patients with severe, difficult to treat atopic dermatitis: Clinical efficacy, safety and dose finding. J Dermatol Sci. 2015 Oct 28. pii: S0923-1811(15)30065-7. doi: 10.1016/j.jdermsci.2015.10.013. [Epub ahead of print]

50. Siest G(1), Auffray C(2), Taniguchi N(3), Ingelman-Sundberg M(4), Murray H(5), Visvikis-Siest S(1), Ansari M(6), Marc J(7), Jacobs P(8), Meyer U(9), Van Schaik RH(10), MÃ¼ller MM(11), Wevers RA(12), Simmaco M(13), Kussmann M(14), Manolopoulos VG(15), Alizadeh BZ(16), Beastall G(17), NÃ©meth G(18). Systems medicine, personalized health and therapy. Pharmacogenomics. 2015 Sep;16(14):1527-39. doi: 10.2217/pgs.15.103. Epub 2015 Sep 24.

51. Blonk MI(1), Langemeijer CC, Colbers AP, Hoogtanders KE, van Schaik RH, Schouwenberg BJ, Burger DM. Pharmacokinetic drug-drug interaction study between raltegravir and citalopram. Antivir Ther. 2015 Sep 16. doi: 10.3851/IMP2993. [Epub ahead of print]

52. Kalman LV(1), AgÃºndez JA(2), Appell ML(3), Black JL(4), Bell GC(5), Boukouvala S(6), Bruckner C(7), Bruford E(8), Bruckner C(7), Caudle K(9), Coulthard S(10), Daly AK(11), Del Tredici AL(12), den Dunnen JT(13), Drozda K(14), Everts R(15), Flockhart D(16), Freimuth R(17), Gaedigk A(18), HachadH(19), Hartshorne T(20), Ingelman-Sundberg M(21), Klein TE(22), Lauschke VM(23), Maglott DR(24),McLeod HL(25), McMillin GA(26), Meyer UA(27), MÃ¼ller DJ(28), Nickerson DA(29), Oetting WS(30),Pacanowski M(31), Pratt VM(32), Relling MV(33), Roberts A(34), Rubinstein WS(24), Sangkuhl K(35),Schwab M(36), Scott SA(37), Sim SC(38), Thirumaran RK(39), Toji LH(40), Tyndale R(41), van Schaik RH(42), Whirl-Carrillo M(43), Yeo KJ(44), Zanger UM(45). Pharmacogenetic Allele Nomenclature: International Workgroup Recommendations for Test Result Reporting. Clin Pharmacol Ther. 2015 Oct 19. doi: 10.1002/cpt.280. [Epub ahead of print]

53. Binkhorst L(1), Kloth JS, de Wit AS, de Bruijn P, Lam MH, Chaves I, Burger H, van Alphen RJ, Hamberg P, van Schaik RH, Jager A, Koch BC, Wiemer EA, van Gelder T, van der Horst GT, Mathijssen RH. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Breast Cancer Res Treat. 2015 Jul;152(1):119-28. doi: 10.1007/s10549-015-3452-x. Epub 2015 Jun 7.

2014

54. van Gelder T(1), van Schaik RH(2), Hesselink DA(3). Practicability of pharmacogenetics in transplantation medicine. Clin Pharmacol Ther. 2014 Mar;95(3):262-4. doi: 10.1038/clpt.2013.169. Epub 2013 Aug 29.

55. Elens L(1), Bouamar R, Shuker N, Hesselink DA, van Gelder T, van Schaik RH. Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. Br J Clin Pharmacol. 2014 Apr;77(4):715-28. doi: 10.1111/bcp.12253.

56. Gijsen VM(1), van Schaik RH, Soldin OP, Soldin SJ, Nulman I, Koren G, de Wildt SN. P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a



pilot study. Ther Drug Monit. 2014 Apr;36(2):152-8. doi: 10.1097/FTD.0b013e3182a3f282.

57. Elens L(1), Hesselink DA, Bouamar R, Budde K, de Fijter JW, De Meyer M, Mourad M, Kuypers DR, Haufroid V, van Gelder T, van Schaik RH. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Ther Drug Monit. 2014 Feb;36(1):71-9. doi: 10.1097/FTD.0b013e31829da6dd.

58. Hesselink DA(1), Bouamar R, Elens L, van Schaik RH, van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014 Feb;53(2):123-39. doi: 10.1007/s40262-013-0120-3.

59. Dezentjé VO, Gelderblom H, Van Schaik RH, Vletter-Bogaartz JM, Van der Straaten T, Wessels JA, Kranenbarg EM, Berns EM, Seynaeve C, Putter H, Van de Velde CJ, Nortier JW, Guchelaar HJ. CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifenexemestane adjuvant multinational (TEAM) trial. Breast Cancer Res Treat. 2014 Jan;143(1):171-9. doi: 10.1007/s10549-013-2777-6. (IF: 4.4)

60. van der Pas R, van Esch JH, de Bruin C, Danser AH, Pereira AM, Zelissen PM, Netea-Maier R, Sprij-Mooij DM, van den Berg-Garrelds IM, van Schaik RH, Lamberts SW, van den Meiracker AH, Hofland LJ, Feelders RA. Cushing`s disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy. Eur J Endocrinol. 2014 Feb 1;170(2):181-91. doi: 10.1530/EJE-13-0477. Print 2014.

61. Chen Z(1), Bouamar R, Van Schaik RH, De Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DR, Weimar W, Hesselink DA, Van Gelder T. Genetic polymorphisms in IL-2, IL-10, TGF-Î²1, and IL-2RB and acute rejection in renal transplant patients. Clin Transplant. 2014 Mar 1. doi: 10.1111/ctr.12346. [Epub ahead of print]

62. Ragia G(1), Tavridou A(1), Elens L(2), Van Schaik RH(3), Manolopoulos VG(1). CYP2C9*2 Allele Increases Risk for Hypoglycemia in POR*1/*1 Type 2 Diabetic Patients Treated with Sulfonylureas. Exp Clin Endocrinol Diabetes. 2014 Jan;122(1):60-3. doi: 10.1055/s-0033-1361097. Epub 2014 Jan 24.

63. Ragia G, Kolovou V, Tavridou A, Elens L, Tselepis AD, Elisaf M, Van Schaik RH, Kolovou G, Manolopoulos VG. Lack of Association of the P450 Oxidoreductase *28 Single Nucleotide Polymorphism with the Lipid-Lowering Effect of Statins in Hypercholesterolemic Patients. Mol Diagn Ther. 2014 Jan 16. [Epub ahead of print]

64. Siest G(1), Medeiros R, Melichar B, Stathopoulou M, Van Schaik RH, Cacabelos R, Abt PM, Monteiro C, Gurwitz D, Queiroz J, Mota-Filipe H, Ndiaye NC, Visvikis-Siest S. Pharmacogenomics: from cell to clinic (Part 1). Pharmacogenomics. 2014 Apr;15(5):593-9. doi: 10.2217/pgs.14.35.

65. Siest G(1), Medeiros R, Melichar B, Stathopoulou M, Van Schaik RH, Cacabelos R, Abt PM, Monteiro C, Gurwitz D, Queiroz J, Mota-Filipe H, Ndiaye NC, Visvikis-Siest S. Conference Scene: Pharmacogenomics: from cell to clinic (Part 2). Pharmacogenomics. 2014 Apr;15(6):739-44. doi: 10.2217/pgs.14.36.

66. Li P(1), Shuker N, Hesselink DA, van Schaik RH, Zhang X, van Gelder T. Do Asian renal transplant patients need another mycophenolate mofetil dose compared to Caucasian or African American patients? Transpl Int. 2014 Jun 25. doi: 10.1111/tri.12382. [Epub ahead of print]

67. Kampourakis K(1), Vayena E, Mitropoulou C, van Schaik RH, Cooper DN, Borg J, Patrinos GP. Key challenges for next-generation pharmacogenomics: Science & Society series on Science and Drugs. EMBO Rep. 2014 May;15(5):472-6. doi: 10.1002/embr.201438641. Epub 2014 Apr 10.

68. Lane K(1), Dixon JJ, McKeown D, Johnston A, van Schaik RH, van Fessem M, MacPhee IA, Philips BJ. Using tramadol to measure CYP2D6 metabolism in critically ill adults. Intensive Care Med. 2014 Jun 27. [Epub ahead of print]

69. Tapirdamaz O(1), Hesselink DA, El Bouazzaoui S, Azimpour M, Hansen B, van der Laan LJ, Polak WG, Kwekkeboom J, van Schaik RH, van Gelder T, Metselaar HJ. Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation. Pharmacogenet Genomics. 2014 Jul 10. [Epub ahead of print]

70. Schröder FH(1), Hugosson J(2), Roobol MJ(3), Tammela TL(4), Zappa M(5), Nelen V(6), Kwiatkowski M(7), Lujan M(8), MÃ¤Ã¤ttÃ¤nen L(9), Lilja H(10), Denis LJ(11), Recker F(12), Paez A(13), Bangma CH(3), Carlsson S(14), Puliti D(5), Villers A(15), Rebillard X(16), Hakama M(17), Stenman UH(18), Kujala P(19), Taari K(20), Aus G(21), Huber A(22), van der Kwast TH(23), van Schaik RH(24), de Koning HJ(25), Moss SM(26), Auvinen A(27); for the ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014 Aug 6. pii: S0140-6736(14)60525-0. doi: 10.1016/S0140-6736(14)60525-0. [Epub ahead of print]

71. Moes AD(1), Hesselink DA, Zietse R, van Schaik RH, van Gelder T, Hoorn EJ. Calcineurin inhibitors and hypertension: a role for pharmacogenetics? Pharmacogenomics. 2014 Jun;15(9):1243-



51. doi: 10.2217/pgs.14.87.

72. Mizzi C(1), Peters B, Mitropoulou C, Mitropoulos K, Katsila T, Agarwal MR, van Schaik RH, Drmanac R, Borg J, Patrinos GP. Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics. 2014 Jun;15(9):1223-34. doi: 10.2217/pgs.14.102.

73. van Gelder T(1), van Schaik RH(2), Hesselink DA(3). Pharmacogenetics and immunosuppressivedrugs in solid organ transplantation. Nat Rev Nephrol. 2014 Sep 23. doi: 10.1038/nrneph.2014.172. [Epub ahead of print]

74. Mitropoulou C(1), Mai Y, van Schaik RH, Vozikis A, Patrinos GP. Stakeholder Analysis in Pharmacogenomics and Genomic Medicine in Greece. Public Health Genomics. 2014 Sep 9. [Epub ahead of print]

75. Ragia G, Kolovou V, Tavridou A, Elens L, Tselepis AD, Elisaf M, Van Schaik RH, Kolovou G, Manolopoulos VG. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia. Drug Metabol Drug Interact. 2014 Sep 30. pii: /j/dmdi.ahead-of-print/dmdi-2014-0021/dmdi-2014-0021.xml. doi: 10.1515/dmdi-2014-0

76. de Jonge H(1), Elens L(2), de Loor H(1), van Schaik RH(3), Kuypers DR(1). The CYP3A4*22 C>Tsingle nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. Pharmacogenomics J. 2014 Oct 7. doi: 10.1038/tpj.2014.49. [Epub ahead of print]

77. Leusink M(1), de Keyser CE, Onland-Moret NC, Hofman A, Visser LE, Stricker BH, de Bakker PI, Boer Ad, van Schaik RH, Maitland-van der Zee AH. No association between CYP3A4*22Â and statin effectiveness in reducing the risk for myocardial infarction. Pharmacogenomics. 2014 Aug;15(11):1471-7. doi: 10.2217/pgs.14.90.

78. Matic M(1), Norman E, Rane A, Beck O, Andersson M, Elens L, Tibboel D, Fellman V, van Schaik RH. Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort. Pharmacogenomics. 2014 Sep;15(12):1589-97. doi: 10.2217/pgs.14.115.

79. Loeb S(1), Sanda MG(2), Broyles DL(3), Shin SS(3), Bangma CH(4), Wei JT(5), Partin AW(6), Klee GG(7), Slawin KM(8), Marks LS(9), van Schaik RH(10), Chan DW(11), Sokoll LJ(11), Cruz AB(3), Mizrahi IA(3), Catalona WJ(12). The Prostate Health Index (phi) Selectively Identifies Clinically-Significant Prostate Cancer. J Urol. 2014 Nov 15. pii: S0022-5347(14)04900-3. doi: 10.1016/j.juro.2014.10.121. [Epub ahead of print]

80. Drogari E(1), Ragia G, Mollaki V, Elens L, Van Schaik RH, Manolopoulos VG. POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. Pharmacogenomics. 2014 Dec;15(16):1963-72. doi: 10.2217/pgs.14.138.

81. Vinkers DJ, Bogaerts S, Van Schaik RH. MAOA, COMT and 5-HTTLPR frequencies in convicted and never convicted Afro-Caribbeans in the Netherlands. Crim Behav Ment Health. 2014 Dec;24(5):365-7. doi: 10.1002/cbm.1908.

2013

82. de Graan AJ, Elens L, Smid M, Martens JW, Sparreboom A, Nieuweboer AJ, Friberg LE, Elbouazzaoui S, Wiemer EA, van der Holt B, Verweij J, van Schaik RH, Mathijssen RH. A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clin Cancer Res. 2013 Sep 15;19(18):5210-7. doi: 10.1158/1078-0432.CCR-13-0487. (IF: 7.7)

83. de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, de Raaf PJ, de Bruijn P, Engels FK, Eskens FA, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res. 2013 Jun 15;19(12):3316-24. doi: 10.1158/1078-0432.CCR-12-3786. (IF: 7.7)

84. Koch BC, van Schaik RH, van Gelder T, Mathijssen RH; Rotterdam Clinical Pharmacology-Pharmacogenetics Group (RCPPG). Doubt about the feasibility of preemptive genotyping. Clin Pharmacol Ther. 2013 Mar;93(3):233. doi: 10.1038/clpt.2012.191. (IF: 6.0)

85. Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Hauptmann M, van Schaik RH, Berns EM, Vermorken JB, van Diest PJ, Linn SC. CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Res Treat. 2013 Jun;139(3):649-55. doi: 10.1007/s10549-013-2568-0. (IF: 4.4)

86. Dezentjé VO, van Schaik RH, Vletter-Bogaartz JM, van der Straaten T, Wessels JA, Kranenbarg EM, Berns EM, Seynaeve C, Putter H, van de Velde CJ, Nortier JW, Gelderblom H, Guchelaar HJ. CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Res Treat. 2013 Jul;140(2):363-73. doi:



10.1007/s10549-013-2619-6. (IF: 4.4)

87. de Keyser CE, Becker ML, Uitterlinden AG, Hofman A, Lous JJ, Elens L, Visser LE, van Schaik RH, Stricker BH. Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenomics. 2013 Aug;14(11):1295-304. doi: 10.2217/pgs.13.112. (IF: 4.0)

88. Elens L, Nieuweboer A, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, Mathijssen RH, van Schaik RH. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics. 2013 Jan;14(2):137-49. doi: 10.2217/pgs.12.202. (IF: 4.0)

89. Elens L, van Gelder T, Hesselink DA, Haufroid V, van Schaik RH. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics. 2013 Jan;14(1):47-62. doi: 10.2217/pgs.12.187. (IF: 4.0)

90. Gijsen VM, van Schaik RH, Elens L, Soldin OP, Soldin SJ, Koren G, de Wildt SN. CYP3A4*22 andCYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics. 2013 Jul;14(9):1027-36. doi: 10.2217/pgs.13.80. (IF: 4.0)

91. Elens L, Nieuweboer AJ, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, van Gelder T, Mathijssen RH, van Schaik RH. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenet Genomics. 2013 Mar;23(3):148-55. doi: 10.1097/FPC.0b013e32835dc113. (IF: 3.5)

92. Elens L, Sombogaard F, Hesselink DA, van Schaik RH, van Gelder T. Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-Î± are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Pharmacogenet Genomics. 2013 Dec;23(12):649-57. doi: 10.1097/FPC.0000000000000001. (IF: 3.5)

93. Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, van Schaik RH. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? J Pain Res. 2013 May 1;6:331-53. doi: 10.2147/JPR.S42040. (IF: 3.5)

94. de Geus HR, Betjes MG, van Schaik RH, Groeneveld JA. Plasma NGAL similarly predicts acute kidney injury in sepsis and nonsepsis. Biomark Med. 2013 Jun;7(3):415-21. doi: 10.2217/bmm.13.5. (IF: 3.2)

95. Ahlers SJ, Elens LL, van Gulik L, van Schaik RH, van Dongen EP, Bruins P, Tibboel D, Knibbe CA.The Val158Met polymorphism of the COMT gene is associated with increased pain sensitivity in morphine-treated patients undergoing a painful procedure after cardiac surgery. Br J Clin Pharmacol. 2013 Jun;75(6):1506-15. doi: 10.1111/bcp.12052. (IF: 2.9)

96. Elens L, Hesselink DA, van Schaik RH, van Gelder T. The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. Br J Clin Pharmacol. 2013 Jun;75(6):1545-7. doi: 10.1111/bcp.12038. (IF: 2.9)

97. Elens L, Capron A, van Schaik RH, De Meyer M, De Pauw L, Eddour DC, Latinne D, Wallemacq P, Mourad M, Haufroid V. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit. 2013Oct;35(5):608-16. doi: 10.1097/FTD.0b013e318296045b. (IF: 2.5)

98. Vafadari R, Bouamar R, Hesselink DA, Kraaijeveld R, van Schaik RH, Weimar W, Baan CC, van Gelder T. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. Ther Drug Monit. 2013 Aug;35(4):459-65. doi: 10.1097/FTD.0b013e31828c1581. (IF: 2.5)

99. Choong E, Loryan I, Lindqvist M, Nordling, Bouazzaoui S, van Schaik RH, Johansson I, Jakobsson J, Ingelman-Sundberg M. Sex difference in formation of propofol metabolites: a replication study. Basic Clin Pharmacol Toxicol. 2013 Aug;113(2):126-31. doi: 10.1111/bcpt.12070.. (IF: 2.1)

100. de Graaff LC, van Schaik RH, van Gelder T. A clinical approach to pharmacogenetics. Neth J Med. 2013 Apr;71(3):145-52. (IF: 2.1)

101. de Geus HR, Fortrie G, Betjes MG, van Schaik RH, Groeneveld AJ. Time of injury affects urinary biomarker predictive values for acute kidney injury in critically ill, non-septic patients. BMC Nephrol. 2013 Dec 9;14(1):273. doi: 10.1186/1471-2369-14-273. (IF: 1.6)

102. Deneer VH, van Schaik RH. Evidence based drug dosing and pharmacotherapeutic recommendations per genotype. Methods Mol Biol. 2013;1015:345-54. doi: 10.1007/978-1-62703-435-7_23. (IF: 1.3)

103. Glubb DM, Paugh SW, van Schaik RH, Innocenti F. A guide to the current web-based resources in pharmacogenomics. Methods Mol Biol. 2013;1015:293-310. doi: 10.1007/978-1-62703-435-7_19. (IF: 1.3)



104. van Schaik RH. New challenges for pharmacogenomics. Drug Metabol Drug Interact. 2013 Dec 1;28(4):191-2. doi: 10.1515/dmdi-2013-0060. (IF: -)

105. Loryan I, Lindqvist M, Johansson I, Hiratsuka M, van der Heiden I, van Schaik RH, Jakobsson J, Ingelman-Sundberg M. Influence of sex on propofol metabolism, a pilot study: implications for propofolanesthesia. Eur J Clin Pharmacol. 2012 Apr;68(4):397-406.

2012

106. Hunfeld NG, Touw DJ, Mathot RA, van Schaik RH, Kuipers EJ. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther. 2012 Apr;35(7):810-8. doi: 10.1111/j.1365-2036.2012.05014.x.

107. Heil SG, van der Ende ME, Schenk PW, van der Heiden I, Lindemans J, Burger D, van Schaik RH. Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals. Ther Drug Monit. 2012 Apr;34(2):153-9.

108. Mitropoulos K, Innocenti F, van Schaik RH, Lezhava A, Tzimas G, Kollia P, Macek M, Fortina P, Patrinos GP. Institutional Profile: Golden Helix Institute of Biomedical Research: interdisciplinary research and educational activities in pharmacogenomics and personalized medicine. Pharmacogenomics. 2012 Mar;13(4):387-92.

109. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics. 2012 Mar 16.

110. van Dijk SC, de Herder WW, Kwekkeboom DJ, Zillikens MC, Feelders RA, van Schaik RH, van Driel M, van Leeuwen JP. 5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients. Bone. 2012 Mar 8.

111. Mutwa PR, Fillekes Q, Malgaz M, Tuyishimire D, van de Kraats R, Boer KR, Burger DM, van Schaik RH, Muganga N, Geelen SP. Middosing interval efavirenz plasma concentrations in HIV-1 infected children in Rwanda: treatment efficacy, tolerability, adherence and the influence of CYP2B6 polymorphisms. J Acquir Immune Defic Syndr. 2012 Apr 4.

112. Sokoll LJ, Chan DW, Klee GG, Roberts WL, van Schaik RH, Arockiasamy DA, Broyles DL, Carlson CM, Mizrahi IA, Pierson TB, Tam JE. Multi-center analytical performance evaluation of the Access Hybritech p2PSA immunoassay. Clin Chim Acta. 2012 Apr 20.

113. Bouamar R, Elens L, Shuker N, van Schaik RH, Weimar W, Hesselink DA, van Gelder T. Mycophenolic Acid-Related Anemia and Leucopenia in Renal Transplant Recipients Are Related to Genetic Polymorphisms in CYP2C8. Transplantation. 2012 May 27;93(10):e39-40.

114. Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Moghaddam-Helmantel IM, de Jonge E, Jager A, Seynaeve C, van Schaik RH, Verweij J, Mathijssen RH. Effects of CYP Induction by Rifampicin on Tamoxifen Exposure. Clin Pharmacol Ther. 2012 Jul;92(1):62-7. doi: 10.1038/clpt.2011.372..

115. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, de Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen T, Walker AL, Du G, Loos WJ, van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A. Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel. Clin Cancer Res. 2012 Jun 18.

116. Roobol MJ, Zhu X, Schröder FH, van Leenders GJ, van Schaik RH, Bangma CH, Steyerberg EW. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. Eur Urol. 2012 Jul 20.

117. Elens L, Hesselink DA, van Schaik RH, van Gelder T. The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. Br J Clin Pharmacol. 2012 Nov 16. doi: 10.1111/bcp.12038.

118. Elens L, Hesselink DA, van Schaik RH, van Gelder T. Pharmacogenetics in Kidney Transplantation : Recent Updates and Potential Clinical Applications. Mol Diagn Ther. 2012 Nov 29.

119. de Rotte MC, Bulatovic M, Heijstek MW, Jansen G, Heil SG, van Schaik RH, Wulffraat NM, de Jonge R. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J Rheumatol. 2012 Oct;39(10):2032-40. doi: 10.3899/jrheum.111593.

120. Loeb S, Sokoll LJ, Broyles DL, Bangma CH, van Schaik RH, Klee GG, Wei JT, Sanda MG, Partin AW, Slawin KM, Marks LS, Mizrahi IA, Shin SS, Cruz AB, Chan DW, Roberts WL, Catalona WJ. Prospective, Multi-Center Evaluation of the Beckman Coulter Prostate Health Index Using WHO



Calibration. J Urol. 2012 Nov 30. pii: S0022-5347(12)05770-9. doi: 10.1016/j.juro.2012.11.149.

121. Ahlers SJ, Elens LL, Gulik LV, Schaik RH, Dongen EP, Bruins P, Tibboel D, Knibbe CA. The Val158Met polymorphism of the COMT gene is associated with increased pain sensitivity in morphine treated-patients undergoing a painful procedure after cardiac surgery. Br J Clin Pharmacol. 2012 Dec 4. doi: 10.1111/bcp.12052.

122. Koch BC, van Schaik RH, van Gelder T, Mathijssen RH. Doubt About the Feasibility of Preemptive Genotyping. Clin Pharmacol Ther. 2012 Dec 12. doi: 10.1038/clpt.2012.191.

2011

123. Elens L, van Schaik RH, Panin N, de Meyer M, Wallemacq P, Lison D, Mourad M, Haufroid V. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics. 2011 Sep 8; [Epub ahead of print]

124. Elens L, Becker ML, Haufroid V, Hofman A, Visser LE, Uitterlinden AG, Stricker BC, van Schaik RH. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study. Pharmacogenet Genomics. 2011 Sep 22;

125. Becker ML, Elens LL, Visser LE, Hofman A, Uitterlinden AG, van Schaik RH, Stricker BH. Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. Pharmacogenomics J. 2011 Dec 20;

126. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH.A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients. Clin Chem. 2011 Sep 8; [Epub ahead of print]

127. van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, Seynaeve C, Lindemans J, Wesseling J, Van `t Veer LJ, Span PN, van Laarhoven H, Sleijfer S, Foekens JA, Linn SC, Berns EM. The CYP2C19*2 genotype predicts tamoxifen treatment outcome inadvanced breast cancer patients. Pharmacogenomics. 2011 Aug 10

128. Loryan I, Lindqvist M, Johansson I, Hiratsuka M, van der Heiden I, van Schaik RH, Jakobsson J, Ingelman-Sundberg M. Influence of sex on propofol metabolism, a pilot study: implications for propofolanesthesia. Eur J Clin Pharmacol. 2011 Oct 18;

129. Bouamar R, Hesselink DA, van Schaik RH, Weimar W, Macphee IA, de Fijter JW, Gelder T. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are Not Associated With Cyclosporine Pharmacokinetics Nor With Cyclosporine Clinical End Points After Renal Transplantation. Ther Drug Monit. 2011 Apr;33(2):178-84.

130. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics. 2011 Feb;12(1):79-82. Epub 2010 Aug 1.

131. Loos WJ, de Graan AJ, de Bruijn P, van Schaik RH, van Fessem MA, Lam MH, Mathijssen RH, Wiemer EA. Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal. 2011 Jan 25;54(2):387-94.

132. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ. Pharmacogenetics: From Bench to Byte- An Update of Guidelines. Clin Pharmacol Ther. 2011 Mar 16;

133. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011 May;185(5):1650-5. Epub 2011 Mar 17.

134. Piana C, Surh L, Furst-Recktenwald S, Iolascon A, Jacqz-Aigrain E, Jonker I, Russo R, van Schaik RH, Wessels J, Della Pasqua OE. Integration of Pharmacogenetics and Pharmacogenomics in Drug Development: Implications for Regulatory and Medical Decision Making in Pediatric Diseases.J Clin Pharmacol. 2011 May 23;

135. Pashaee N, Bouamar R, Hesselink DA, Roodnat JI, van Schaik RH, Weimar W, van Gelder T. CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance. Ther Drug Monit.2011 Jun;33(3):369-71.

136. Manolopoulos VG, Dechairo B, Huriez A, Kuhn A, Llerena A, van Schaik RH, Yeo KT, Ragia G, Siest G. Pharmacogenomics and personalized medicine in clinical practice. Pharmacogenomics.



2011 May;12(5):597-610.

137. de Wildt SN, van Schaik RH, Soldin OP, Soldin SJ, Brojeni PY, van der Heiden IP, Parshuram C, Nulman I, Koren G. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur J Clin Pharmacol. 2011 Jun 23

138. Rakhmanina NY, Neely MN, Van Schaik RH, Gordish-Dressman HA, Williams KD, Soldin SJ, van den Anker JN. CYP3A5, ABCB1, and SLCO1B1 Polymorphisms and Pharmacokinetics and Virologic Outcome of Lopinavir/Ritonavir in HIV-Infected Children. Ther Drug Monit. 2011 Aug;33(4):417-424.

139. de Graan AJ, Teunissen SF, de Vos FY, Loos WJ, van Schaik RH, de Jongh FE, de Vos AI, van Alphen RJ, van der Holt B, Verweij J, Seynaeve C, Beijnen JH, Mathijssen RH. Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment. J Clin Oncol. 2011 Jul 18;

140. Bouamar R, Hesselink DA, van Schaik RH, Weimar W, Heiden IP, de Fijter JW, Kuypers DR, vanGelder T. Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. Pharmacogenet Genomics. 2011 Aug 29;

2010

141. Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C, van Fessem MA,Berns EM, Vulto AG, van Schaik RH. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer. 2010 Sep 7;103(6):765-71.

142. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics. 2010 Aug 1;

143. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics. 2010 Jan;20(1):38-44.

144. Blonk MI, van der Velde N, van den Bemt PM, van Schaik RH, van der Cammen TJ. CYP2D6*4,CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls in elderly people. Pharm World Sci. 2010 Feb;32(1):26-9..

145. van der Straaten T, van Schaik RH. Genetic techniques for pharmacogenetic analyses. Curr Pharm Des. 2010;16(2):231-7.

146. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, Wildhagen MF, Roobol MJ, Bangma CH, Bartsch G. Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection. Eur Urol. 2010 Feb 13;

147. van Luin M, Van der Ende ME, Richter C, Visser M, Faraj D, Van der Ven A, Gelinck L, Kroon F, Wit FW, Van Schaik RH, Kuks PF, Burger DM. Lower atovaquone/proguanil concentrations in patientstaking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. AIDS. 2010 May 15;24(8):1223-6.

148. Rakhmanina NY, van den Anker JN, Soldin SJ, van Schaik RH, Mordwinkin N, Neely MN. Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? Ther Drug Monit. 2010 Jun;32(3):273-81.

149. Siemes C, Visser LE, de Jong FH, Coebergh JW, Uitterlinden AG, Hofman A, Stricker BH, van Schaik RH. Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer--The Rotterdam Study. Steroids. 2010 Dec;75(12):1024-32.

150. Gensburger O, Van Schaik RH, Picard N, Le Meur Y, Rousseau A, Woillard JB, Van Gelder T, Marquet P. Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Pharmacogenet Genomics. 2010 Sep;20(9):537-43.

151. Schenk PW, van Vliet M, Mathot RA, van Gelder T, Vulto AG, van Fessem MA, Verploegh-Van Rij S, Lindemans J, Bruijn JA, van Schaik RH. The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. Pharmacogenomics J. 2010 Jun;10(3):219-25.

152. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf. 2010 Jan;19(1):75-81.

2009

153. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009 Feb;85(2):155-63.



154. Bijl MJ, Visser LE, van Schaik RH, Kors JA, Witteman JC, Hofman A, Vulto AG, van Gelder T, Stricker BH. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin Pharmacol Ther. 2009 Jan;85(1):45-50.

155. Teichert M, van Schaik R, Hofman A, Uitterlinden A, de Smet P, Stricker B, Visser L. Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of AcenocoumarolAnticoagulation During the Initial Treatment Period. Clin Pharmacol Ther. 2009 Feb 18;

156. Bijl MJ, van Schaik RH, Lammers LA, Hofman A, Vulto AG, van Gelder T, Stricker BH, Visser LE.The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat. 2009 Feb 3; [

157. van Luin M, Brouwer AM, van der Ven A, de Lange W, van Schaik RH, Burger DM. Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin. AIDS. 2009 Mar 27;23(6):742-4.

158. Bijl MJ, Luijendijk HJ, van den Berg JF, Visser LE, van Schaik RH, Hofman A, Vulto AG, van Gelder T, Tiemeier H, Stricker BH. Association between the CYP2D6*4 polymorphism and depressionor anxiety in the elderly. Pharmacogenomics. 2009 Apr;10(4):541-7.

159. Kwadijk-de Gijsel S, Bijl MJ, Visser LE, van Schaik RH, Hofman A, Vulto AG, van Gelder T, Ch Stricker BH. Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants. Br J Clin Pharmacol. 2009 Aug;68(2):221-5.

160. Siemes C, Eijgelsheim M, Dieleman JP, van Schaik RH, Uitterlinden AG, van Duijn CM, Hofman A, Coebergh JW, Stricker BH, Visser LE. No modification of the beneficial effect of NSAIDs on colorectal cancer by CYP2C9 genotype. Neth J Med. 2009 Apr;67(4):134-41.

161. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A, De Smet PA, van Gelder T, Visser LE, Stricker BH. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet. 2009 Jul 4; [Epub ahead of print]

162. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Ch Stricker BH. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf. 2009 Oct 2; [Epub ahead of print]

163. Bliek BJ, van Schaik RH, van der Heiden IP, Sayed-Tabatabaei FA, van Duijn CM, Steegers EA, Steegers-Theunissen RP; Eurocran Gene-Environment Interaction Group. Maternal medication use, carriership of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate. Am J Med Genet A. 2009 Oct;149A(10):2088-92.

164. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variationin the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes. 2009 Mar;58(3):745-9.

165. van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, Kuypers D, Le Meur Y, van der Werf M, Mamelok R, van Gelder T. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther. 2009 Sep;86(3):319-27..

166. Sombogaard F, van Schaik RH, Mathot RA, Budde K, van der Werf M, Vulto AG, Weimar W, Glander P, Essioux L, van Gelder T. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet Genomics. 2009 Aug;19(8):626-34.

2008

167. van Schaik RHN. CYP450 pharmacogenetics for personalized cancer therapy. Drug Rest Updates 2008 Jun;11(3):77-98.

168. van Agteren M, Armstrong VW, van Schaik RH, de Fijter H, Hartmann A, Zeier M, Budde K, Kuypers D, Pisarski P, Le Meur Y, van der Werf M, Mamelok RD, Oellerich M, van Gelder T. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. Ther Drug Monit. 2008 Aug;30(4):439-44.

169. Hesselink DA, van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DR, Pisarski P, Meur YL, Mamelok RD, van Gelder T. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics. 2008 Apr;18(4):339-348.

170. Aarnoudse AJ, Dieleman JP, Visser LE, Arp PP, van der Heiden IP, van Schaik RH, Molokhia M, Hofman A, Uitterlinden AG, Stricker BH. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics. 2008 Apr;18(4):299-305.

171. Allegaert K, van den Anker JN, de Hoon JN, van Schaik RH, Debeer A, Tibboel D, Naulaers G,



Anderson BJ. Covariates of tramadol disposition in the first months of life. Br J Anaesth. 2008 Apr;100(4):525-32.

172. Allegaert K, van Schaik RH, Vermeersch S, Verbesselt R, Cossey V, Vanhole C, van Fessem M, de Hoon J, van den Anker JN. Postmenstrual age and CYP2D6 polymorphisms determine tramadol O-demethylation in critically ill neonates and infants. Pediatr Res. 2008 Feb 27; [Epub ahead of print]

173. Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol. 2008 Mar;83(3):200-2.

174. Teichert M, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, De Smet PA, Witteman JC, Stricker BH. Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Polymorphism and Aortic Calcification. The Rotterdam Study. Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):771-6

175. Hunfeld NG, Mathot RA, Touw DJ, van Schaik RH, Mulder PG, Franck PF, Kuipers EJ, Geus WP. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol. 2008 Jan 30; [Epub ahead of print]

176. Bijl MJ, Visser LE, Hofman A, Vulto AG, van Gelder T, Stricker BH, van Schaik RH. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol. 2008 Apr;65(4):558-64

177. Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol. Am J Hematol. 2008 Mar;83(3):200-2.

178. Schenk PW, van Fessem MA, Verploegh-Van Rij S, Mathot RA, van Gelder T, Vulto AG, van VlietM, Lindemans J, Bruijn JA, van Schaik RH. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry. 2008 Jun;13(6):597-605.

179. van Schaik RHN, Grandia L, de Goede A, Bet PM, Bekers O, Guchelaar H-J, Goldschmidt HMJ, Meijer MMC, Mulder H, van der Weide J, Deneer VHM Nederlandse consensus: CYP2D6 genotype ‘1-0’ ingedeeld als intermediaire metaboliseerder. Ned Tijdschr Klin Chem Labgeneesk 2008, vol 33, no. 1; 52-53

2007

180. Verzijl A, Heide R, Oranje AP, van Schaik RH. C-kit Asp-816-Val Mutation Analysis in Patients with Mastocytosis. Dermatology. 2007;214(1):15-20.

181. Visser LE, van Schaik RH, Jan Danser AH, Hofman A, Witteman JC, van Duijn CM, Uitterlinden AG, Pols HA, Stricker BH. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet Genomics. 2007 Jul;17(7):473-9.

182. Yazdanpanah M, Aulchenko YS, Hofman A, Janssen JA, Sayed-Tabatabaei FA, van Schaik RH, Klungel OH, Stricker BH, Pols HA, Witteman JC, Lamberts SW, Oostra BA, van Duijn CM. Effects of the renin-angiotensin system genes and salt sensitivity genes on blood pressure and atherosclerosis in the total population and patients with type 2 diabetes. Diabetes. 2007 Jul;56(7):1905-12.

183. Krekels EH, van den Anker JN, Baiardi P, Cella M, Cheng KY, Gibb DM, Green H, Iolascon A, Jacqz-Aigrain EM, Knibbe CA, Santen GW, van Schaik RH, Tibboel D, Della Pasqua OE. Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. Expert Opin Pharmacother. 2007 Aug;8(12):1787-99.

184. Kummeling MT, de Jong BW, Laffeber C, Kok DJ, Verhagen PC, van Leenders GJ, van Schaik RH, van Woerden CS, Verhulst A, Verkoelen CF. Tubular and interstitial nephrocalcinosis. J Urol. 2007 Sep;178(3 Pt 1):1097-103.

185. Levin MD, den Hollander JG, van der Holt B, Rijnders BJ, van Vliet M, Sonneveld P, van Schaik RH. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother. 2007 Nov;60(5):1104-7.

186. Engels FK, Loos WJ, Mathot RA, van Schaik RH, Verweij J. Influence of ketoconazole on the fecal and urinary disposition of docetaxel. Cancer Chemother Pharmacol. 2007 Sep;60(4):569-79.

187. van der Bol JM, Mathijssen RH, Loos WJ, Friberg LE, van Schaik RH, de Jonge MJ, Planting AS, Verweij J, Sparreboom A, de Jong FA. Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on Neutropenia. J Clin Oncol. 2007 Jul 1;25(19):2719-26.]

2006

188. de Bont JM, den Boer ML, Reddingius RE, Jansen J, Passier M, van Schaik RH, Kros JM, Sillevis Smitt PA, Luider TH, Pieters R. Identification of apolipoprotein A-II in cerebrospinal fluid of pediatric brain tumor patients by protein expression profiling. Clin Chem. 2006 Aug;52(8):1501-9..

189. Lee SJ, van der Heiden IP, Goldstein JA, van Schaik RH. A new CYP3A5 variant, CYP3A5*11, is



shown to be defective in nifedipine metabolism in a recombinant cDNA expression system. Drug Metab Dispos. 2006 Oct 11

190. Aarnoudse AL, van Schaik RH, Dieleman J, Molokhia M, van Riemsdijk MM, Ligthelm RJ, Overbosch D, van der Heiden IP, Stricker BH. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther. 2006 Oct;80(4):367-374.

191. Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, Richter C, Koopmans P, Kroon F, Sprenger H, Lindemans J, Schenk P, van Schaik R. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006 Feb;61(2):148-54.

192. Hofland J, Timmerman MA, de Herder WW, van Schaik RH, de Krijger RR, de Jong FH. Expression of activin and inhibin subunits, receptors and binding proteins in Human adrenocortical neoplasms. Clin Endocrinol (Oxf). 2006 Dec;65(6):792-9.

193. Chai W, Hoedemaekers Y, van Schaik RH, van Fessem M, Garrelds IM, Saris J, Dooijes D, ten Cate FJ, Kofflard MM, Danser AH. Cardiac aldosterone in subjects with hypertrophic cardiomyopathy. J Renin Angiotensin Aldosterone Syst. 2006 Dec;7(4):225-30.

194. van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, van der Heiden IP, Wiemer EA, Vossebeld PJ, Lowenberg B, Sonneveld P. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther. 2006 Nov;80(5):427-439.

195. Hesselink DA, van Gelder T, van Schaik RHN Immunosuppressants and MDR-1 and CYP3A polymorphisms Pharmacogenetics and Proteomics, AACC Press 2006, Chapter 23

196. Peeters MY, Prins SA, Knibbe CA, Dejongh J, Mathot RA, Warris C, van Schaik RH, Tibboel D, Danhof M. Pharmacokinetics and Pharmacodynamics of Midazolam and Metabolites in NonventilatedInfants after Craniofacial Surgery. Anesthesiology. 2006 Dec;105(6):1135-1146.

197. Peeters MY, Prins SA, Knibbe CA, DeJongh J, van Schaik RH, van Dijk M, van der Heiden IP, Tibboel D, Danhof M. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology. 2006 Mar;104(3):466-74.

198. de Jong FA, Kehrer DF, Mathijssen RH, Creemers GJ, de Bruijn P, van Schaik RH, Planting AS, van der Gaast A, Eskens FA, Janssen JT, Ruit JB, Verweij J, Sparreboom A, de Jonge MJ. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist. 2006 Sep;11(8):944-54.

199. Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J. Influence of high-dose ketoconazoleon the pharmacokinetics of docetaxel. Cancer Biol Ther. 2006 Jul;5(7):833-9.

200. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther. 2006 Aug;80(2):192-201.

201. Mathijssen RH, van Schaik RH. Genotyping and phenotyping cytochrome P450: perspectives forcancer treatment. Eur J Cancer. 2006 Jan;42(2):141-8.

202. van der Padt A, van Schaik RH, Sonneveld P. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. Neth J Med. 2006 May;64(5):160-2.

2005

203. Smit P, van Schaik RH, van der Werf M, van den Beld AW, Koper JW, Lindemans J, Pols HA, Brinkmann AO, de Jong FH, Lamberts SW. A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J Clin Endocrinol Metab. 2005 Sep;90(9):5313-6.

204. Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther. 2005 Jun;77(6):479-85.

205. Hesselink DA, van Gelder T, van Schaik RH. The pharmacogenetics of calcineurin inhibitors: onestep closer toward individualized immunosuppression? Pharmacogenomics. 2005 Jun;6(4):323-337.

206. Hesselink DA, van Schaik RHN, Weimar W, van Gelder T Tacrolimus, but not cyclosporine dose requirement is correlated with genetic polymorphisms in the CYP3A4 and CYP3A5 genes Daniel den Hoed Cancer News, May 2005: 26-28

207. Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A.



Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res. 2005 Oct 15;11(20):7398-404.

208. Soepenberg O, Dumez H, Verweij J, de Jong FA, de Jonge MJ, Thomas J, Eskens FA, van Schaik RH, Selleslach J, Ter Steeg J, Lefebvre P, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res. 2005 Feb 15;11(4):1504-11.

209. van Schaik RH. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs. 2005 Dec;23(6):513-22.

2004

210. Blijenberg BG, van Schaik RHN Prostaat-specifiek antigeen (PSA): 1984-2004 Analyse, maart 2004

211. van der Heiden IP, van der Werf M, Lindemans J, van Schaik RH. Sequencing: not always the "gold standard". Clin Chem. 2004 Jan;50(1):248-9.

212. Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost. 2004 Jul;92(1):61-6.

213. Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 orCYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics. 2004 Jan;14(1):27-33.

214. Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, van der Werf M, Weimar W, Mathot RA. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther. 2004 Dec;76(6):545-56.

215. van Gelder T, Hesselink DA, van Hest RM, Mathot RA, van Schaik R. Pharmacogenetics in immunosuppressive therapy: the best thing since TDM? Ther Drug Monit. 2004 Aug;26(4):343-6.

216. Wiersma WE, Koopmans RP, Bos AP, van den Berg H, van Aalderen WMC, van Schaik RHN, van den Anker JN Het juiste geneesmiddel voor de juiste patiënt: farmacogenetica in de kindergeneeskundige praktijk Tijdschr Kindergeneeskd 2004; 72:190-197

217. Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res. 2004 Dec 15;10(24):8341-50.

218. Janssen JA, Wildhagen MF, Ito K, Blijenberg BG, Van Schaik RH, Roobol MJ, Pols HA, Lamberts SW, Schroder FH. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with J Clin Endocrinol Metab. 2004 Sep;89(9):4391-6.

219. Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst. 2004 Nov 3;96(21):1585-92.

220. van Schaik RH. Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents. Ther Drug Monit. 2004 Apr;26(2):236-40.

2003

221. Van Schaik RHN. Pharmacogenetics of anticancer agents. IN: Proc 15th IFCC-FESCC European Congres of Clinical Chemistry and Laboratory Medicine, Barcelona. Monduzzi Editore, 2003: 143-148

222. Hesselink DA, van Schaik RHN, van der Heiden IP, van der Werf M, Smak Gregoor PJH, Lindemans J, Weimar W, van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther, 2003: 74:245-54.

2002

223. Van Schaik RHN, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002 Oct; 48:1668-71

2001

224. Baum H, Bersch T, Bohner J, von Pap KW, Hoff T, Wilke B, Luthe H, Luz H, Nagel D,



Niederhausen C, van Schaik RHN, Aschenneller C, Schul I, Zerback R. Detection limit, cut-off and specificity of an improved rapid assay for cardiac troponin T. Clin Lab. 2001; 47: 549-54

225. Van Schaik RHN, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, Lindemans J. TheCYP3A4*3 allele: is it really rare? Clin Chem. 2001; 47: 1104-6

2000

226. Van Schaik RHN, de Wildt SN, van Iperen NM, Uitterlinden AG, van den Anker JN, Lindemans J.CYP3A4-V polymorphism detection by PCR-RFLP and its allelic frequency among 199 Dutch Caucasians. Clin Chem 2000;46:1834-6

227. Van Schaik RHN, Wierikx CDJ, Timmerman MA, Oomen MH, van Weerden WM, van der Kwast TH, et al. Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues. Br J Cancer 2000;82:112-7

1990-1999

228. de Jong FH, Tebar M, Wessels HT, van Schaik RHN. Inhibin and activin: their production and action in normal and abnormal tissues. Rev Arg Endocrinol Metab 1999;36:14 – 16

229. Engelse MA, Neele JM, Agterberg TAE, van Aken BE, van Schaik RHN, Pannekoek H, et al. Human activin A expression is increased in atherosclerotic tissue and induces smooth muscle cell differentiation. Circ Res 1999;85:931-9

230. Griffioen PH, Zwang L, van Schaik RHN, Engel H, Lindemans J, Cobbaert CM. Optimization of apolipoprotein(a) genotyping with pulsed field gel electrophoresis. Clin Chem 1999;45:771-6.

231. Van Schaik RHN, de Wildt SN, Lindemans J. Cytochrome P450-polymorphisms and cancer treatment (Dutch). Ned Tijdschr Klin Chem 1999;24:232-7

232. Caricasole AAD and van Schaik RHN1, Zeinstra LM, Wierikx CDJ, van Gurp RJ, van den Pol M, et al. Human growth-differentiation factor 3 (hGDF3): developmental regulation in human teratocarcinoma cell lines and expression in primary testicular germ cell tumours. Oncogene 1998;16:95-103. (1Shared 1st author)..

233. Uilenbroek JT, Durlinger AL, Tebar M, Kramer P, van Schaik RHN, Wierikx CDJ, et al. Temporal changes in inhibin subunit mRNAs during atresia of preovulatory follicles in the rat. J Endocrinology 1998;159:331-40

234. Caricasole A, van Schaik RHN, Zeinstra LM, Wierikx CDJ, Looijenga LHJ, Oosterhuis JW, Pera MF, de Jong FH, van den Eijnden-van Raaij AJM. Analysis of the response of human embryonla carcinoma cells to activin A. IN: Inhibin, activin and follistatin: regulatory functions in system and cell biology. Eds.: Aono T, Sugino H, Vale WW; Springer Verlag, New York 1997, pp. 308-11.

235. De Jong FH, van Schaik RHN, Wierikx CDJ, de Winter JP, Looijenga LHJ, Oosterhuis JW, Caricasole A, Pera M, van den Eijnden-van Raaij AJM. Expression of inhibin subunits, follistatin and activin receptors in normal testicular cells and testicular tumors. IN: Inhibin, activin and follistatin: regulatory functions in system and cell biology. Eds.: Aono T, Sugino H, Vale WW; Springer Verlag, New York 1997, pp. 76-84.

236. Tébar M, Uilenbroek JT, Kramer P, van Schaik RHN, Wierikx CDJ, Ruiz A, et al. Effects of progesterone on the secondary surge of follicle-stimulating hormone in the rat. Biol Reprod 1997;57:77-84

237. Martens JW, de Winter JP, Timmerman MA, McLuskey A, van Schaik RHN, Themmen AP, et al. Inhibin interferes with activin signaling at the level of the activin receptor complex in Chinese hamster ovary cells. Endocrinology 1997;138:2928-36.

238. Van Schaik RHN, Wierikx CDJ, Looijenga LHJ, Oosterhuis JW, de Jong FH. Human testicular germ cell tumours express inhibin subunits, activin receptors and follistatin mRNAs. Br J Cancer 1997;76:1191-8

239. Tuuri T, Erämaa M, van Schaik RHN, Ritvos O. Differential regulation of inhibin/activin alpha- and beta A-subunit and follistin mRNAs by cyclic AMP and phorbol ester in cultured human granulosa-luteal cells. Mol Cell Endocrinol 1996;121:1-10

240. Van Schaik, RHN, Verhoeven, NM, Neijs, FW, Aarsman, AJ and van den Bosch, H (1992). Cloning of the cDNA coding for 14 kDA group II phospholipase A2 from rat liver. Biochim Biophys Acta1169, 1-11.

241. Van Schaik, RHN, van den Koedijk, CDMA, Meijs, FW, Aarsman, AJ and van den Bosch, H (1992). Monoclonal antibodies against rat liver mitochondrial phospholipas A2: epitope analysis and application in Western blotting. Int J Biochem 25, 433-439.

242. Van den Bosch, H, Aarsman, AJ, van Schaik, RHN, Schalkwijk, CG, Neijs, FW and Sturk, A (1990). Structural and enzymological properties of cellular phospholipases. Biochem Soc Trans 19,



781-785.

Projects 2011: MRACE grant: 4OH cholesterol as a CYP3A4 endogenous markers (PI)

2010: Dutch Cancer Society (KWF): Pharmacogenetics of taxanes (PI)

2010: ZONMW – Priority Medicines Children Pharmacokinetic, efficacy and long

term effects of Metformin in adolescents with type 2 diabetes mellitus and/or

obesity resistance. (PI: MMJ van der Vorst).

2010 ZONMW –Priority Medicines Elderly . Utilisation, effectiveness, and

adverse effects of antidepressants in the elderly. (PI: LE Visser).

2009: EU- FP7 grant NeoOpioid: Less pain in children (PI: H Lagercranz) Pharmacogenetics of morphine and fentanyl in neonates (PI WP3: €179,000)

2009 ZONMW: Opioïdrotation for reducing pain in cancer patients: role of

pharmacogenetic heterogeneity. (PI: C. van der Rijt).

2008: Pain Grant: Pharmacogenetics of anti-analgesic (PI D. Burger).

2005: MRACE grant: Pharmacogenetics and anti-HIV drugs (PI)

2005 EU-FP6 Identification of new markers for Prostate Cancer (PI C. Bangma)

2004: Roche Pharma FDCC grant: Pharmacogenetics of transplantation (PI)

1999: MRACE Top-Down grant: Pharmacogenetics of tamoxifen,

antidepressives and chemotherapeutics (PI)

1998: Dutch Society for Scientific Research NWO (travelgrant)

Memberships INTERNATIONAL:

2014-present European Pharmacogenetic Implementation Consortium (chair)

2014-present Genomic Medicine Alliance (member)

2013-present IUPHAR Pharmacogenetics Committee (member)

2013-present EFLM working group Personalized Medicin

2012-2016 AACC Personalized Medicine Division (division officer)

2011-present ESPT (Eur Soc Pharmacogen & Personalised Thrpapy (President)

2010-present European Medicine Agency (EMA) PGWG (advisor)

2008-2017 IFCC Task Force Pharmacogenetics (chair)

2004-2008 IFCC Committee Molecular Biology Diagnostics (member)

2008-present IATDMCT Committee Pharmacogenetics (chair)

2008-2015 EUSPM (European Soc Personalized Medicine) (treasurer)

2006-present ENPR (Eur Network Pharmacogenetic Research) (board)

NATIONAL

2015--present Dutch Clinical Pharmacogenetics Network (www.pgx-net.nl)

2013-present NVKC/NVZA/KNMP Joint working group Clinical Chemistry/Pharmacology (chair)

2006-2013 NVKC Scientific Committee Clinical Chemistry (chair)

2006-present NVKC/CMBD (Committee Molecular Biology Diagnostics) (chair)

2008-present NVKC Task Force Pharmacogenetics (chair)

2007-present KNMP/WinAP (Royal Dutch Pharmacists) Task Force Pharmacogenetic (member)

Other Relevant Information Awards :

2010: AACC Scientific Outstanding Research Award (AACC Annual Meeting, Anaheim)

2009: AACC Outstanding Speaker Award

2008 IFCC Molecular Diagnostic Expert Center Pharmacogenetics

2008: NVKC Sciencific Award (Netherlands Society for Clinical Chemistry)



2001: NVKC Ortho-Clinical Diagnostics award for Clinical Chemistry


Documents

PERSONAL INFORMATION Ronald van Schaik · M(1), van den Broek MPH(4)(5), de Bruin-Weller MS(1). Thiopurine metabolite levels in patients with atopic dermatitis and/or chronic hand/foot